BSD Medical Appoints William Barth as Chief Financial Officer

  BSD Medical Appoints William Barth as Chief Financial Officer

Business Wire

SALT LAKE CITY -- December 11, 2012

BSD Medical Corporation (NASDAQ:BSDM)  (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize heat therapy to treat
cancer, announced the appointment of William S. (Bill) Barth as Chief
Financial Officer and Corporate Secretary. Mr. Barth commenced his employment
with the Company on December 10, 2012, and will assume the duties of Chief
Financial Officer and Corporate Secretary effective January 1, 2013, upon the
departure of Dennis Gauger, current Chief Financial Officer and Corporate
Secretary.

Bill has an extensive history as CFO for both publicly and privately held
companies in the medical device and biotechnology industries. Since May 2011,
he has served as an independent corporate financial and strategic planning
consultant. From June 2008 to May 2011, he served as Sr. Vice President and
Chief Financial Officer for Emphusion, LLC, a private-equity-owned Contract
Research Organization (CRO) providing data management and bio statistical
analysis services for new drug and medical device development. From January
2001 through April 2008 Bill was VP of Finance and CFO for NWT Inc. /Tandem
Labs (Tandem), a privately owned CRO providing advanced bio analytical
services in support of new drug development. Bill was instrumental in the
successful merger of Tandem with Laboratory Corporation of America in February
2008. During the 20 years prior to his experience with Tandem, Bill served as
CFO for 6 medical device companies, two of which were publicly owned. During
this time he played critical roles in completing several equity, debt and
merger transactions. Bill began his career in finance while serving as a staff
accountant with Deloitte & Touche, an international accounting and consulting
firm.

“Bill has proven outstanding competency and experience in all areas of senior
corporate financial management in public and privately held medical device
companies and understands the unique characteristics associated within that
industry,” said Harold Wolcott, BSD President and CEO. “We are pleased Bill is
joining BSD and we look forward to him leading our finance department.”

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
radiofrequency (RF) and microwave energy. BSD’s product lines include both
hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the United
States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to ablate and destroy soft tissue. The Company has
developed extensive intellectual property, multiple products in the market and
well established distribution in the United States, Europe and Asia. Certain
of the Company’s products have received regulatory approvals in the United
States, Europe and China. For further information visit BSD Medical's website
at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.

Contact:

BSD Medical Corporation
Dennis Gauger, 801-972-5555
investor@bsdmc.com
fax: 801-972-5930